What's happening?

When it comes to treating pulmonary diseases, inhalation drugs are highly popular due to their ability to deliver the drug dose directly to where it is needed. However, they do pose challenges for drug developers when it comes to devising new products for the market.

This year, COVID-19 has demonstrated the importance of being prepared for the unexpected. No-one could have predicted an extended crisis like this, with society lockdowns, supply interruptions, and big challenges to overcome to continue business operations.

Patient adherence remains a major consideration for pharmaceutical manufacturers. Medication works effectively only when patients take the right amount at the right time in the right way.

Conceiving and developing a new drug from scratch can be one of the most satisfying experiences you can have. But it is challenging too – it’s by no means certain that your project will succeed and the more cutting-edge your technology, the higher the risk of failure. 

Drug development is an exciting field for any business to work in. However, it is not without its challenges, particularly for pharmaceutical start-ups embarking on developing their own newly discovered drug for the first time. 

The likelihood of failure is high for any drug development project, and the risk of this outcome grows the more revolutionary the product. 

As 2020 is draws to a close, our Chief Executive Officer Thomas Eldered looks back on Recipharm’s key milestones this year in an interview with Nordic Life Science News.

The plant ‘cannabis sativa’, better known as marijuana, has long been used for medical purposes. Around fifty years ago, researchers started to explore the versatility of marijuana following the discovery of ‘∆9-tetrahydrocannabinol’ (THC), the main psychoactive component of approximately 70 phytocannabinoids. 

Rafael W. Hartmann, Raphael Fahrner, Dr. Denys Shevshenko, Prof. Mårten Fyrknäs, Prof. Rolf Larsson, Dr. Fredrik Lehmann, Prof. Luke R. Odell

The auto-injector industry has grown substantially over the last 20 years and is continuing to develop at a rapid rate. This growth is driven by several factors, but particularly the increase in the number of parenteral treatments available for chronic diseases.

The European Union’s good manufacturing practice (GMP) guide for sterile products, known as Annex 1, has been subject to many changes since the first version was published in 1971.